News provided by Eli Lilly and Company Apr 17, 2025, 06:45 ET Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint The overall safety and tolerability profile of orforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone
Beyond cost, the clinical question is whether supplementation addresses your specific metabolic needs
Strengthen Immunity & Support Gut Health: Echinacea extract boosts immune function by stimulating white blood cell production, helping the body fight off infections
L-Glutamine (3.5mg) L-Glutamine is an amino acid that supports gut health and immune function
After completing a short online questionnaire about your health history, if qualified, youll start an on-demand video visit with a Walgreens Weight Management provider
However, peptides lack the large-scale randomized controlled trial evidence that supports biologics